Anticoagulation of pediatric patients with venous thromboembolism in 2023

Venous thromboembolism (VTE) is a rare and heterozygous disease in children. Management of VTE in children is complicated by age -related differences in epidemiology, recurrent VTE and bleeding risk, hemostatic proteins and pharmacokinetics of anticoagulants. Recently, the choice of anticoagulation has expanded to oral factor IIa and Xa inhibitors, which have been authorized for children for treatment of acute VTE and extended secondary prevention. These drugs have several properties that make them extremely suitable for use in children, including oral administration, antithrombin independence, less interactions with food and drugs and no need for monitoring. Unfortunately, the phase 3 studies had many exclusion criteria, and only a few term neonates and infants were included in these studies. Additional real -world data is needed to make evidence -based recommendations in these age and patient groups, as well.